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ORIGINAL RESEARCH
Objective: Consideration of absolute risk has been recommended for making decisions
concerning preventive treatment in hypertension. We performed simulations to estimate the
benefit of antihypertensive therapy over a life-time.
Methodology: The rate of nonfatal and fatal events of untreated hypertensives in the US
population were estimated using data from Individual Data ANalysis of Antihypertensive drug
intervention trials (INDANA; a meta-analysis on individual data in hypertension) and specific
cause of death from national statistics. Disease-free survival curves until all patients have
died were built using the “life-table” method. The treatment effect estimated from INDANA
was applied to this curve to obtain the disease-free survival curve of the life-long treated
population. Gains in event-free life expectancy (GLE) were estimated from survival curves. A
sensitivity analysis was performed to assess the impact of possible death misclassifications.
Results: For a 40-year-old man, the gain in life expectancy without stroke and major
cardiovascular events were 27 and 32 months, respectively, and were more substantial than
those without coronary disease (19 months). The GLE decreased slowly with increasing age
at the beginning of treatment, whereas short-term absolute risk reductions increase sharply
with age.
Conclusions: Policies based on the selection of patients to treat according to absolute benefit
do not maximize the GLE compared with strategies that treat low-risk patients.
Keywords: blood pressure, cardiovascular disease, stroke, coronary artery disease
Introduction
Since randomized clinical trials (RCTs) that included elderly patients have
demonstrated that absolute risk reduction depends on the level of cardiovascular risk
prior to treatment (MacMahon and Rodgers 1993; Lievre and Leizorovicz 1995), the
use of absolute risk as a guide to individual treatment is generally recommended
(JNC 1997; Boissel 1998; Chalmers 1999; Ogden et al 2000). With most treatments
in cardiovascular prevention, absolute risk reduction is proportional to the baseline
risk. Patients with a baseline risk above a pre-defined threshold, with a high probability
of experiencing an event, tend to be defined as the therapy target population because
they will on average benefit more from antihypertensive therapy than patients at low
risk. The decision strategy based on absolute cardiovascular risk has been criticized
(Jackson 1994; Levy 1995; Menard and Chatellier 1995; Krakoff 1996; Swales 1996;
Zanchetti and Mancia 1996), particularly because age is a major determinant of
cardiovascular risk favoring the treatment of elderly population. Yet, the use of RCTs
of short-term duration (between 2 and 6 years) may not provide the best basis for a
decision concerning long-term preventive therapy, particularly for young or middle-
age subjects.
Ideally, a prediction of the treatment effect after the average duration of RCTs
should be available to define which hypertensive patients should be treated? As
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long-term RCTs encounter unresolved ethical issues, long-
term follow-up after the end of the study has been used to
measure the average life prolongation (Cucherat et al 1997;
Swedberg et al 1999).
Another way to fill the gap between the evidence from
short-term RCTs expressed in terms of risk reduction, and
patient expectations of healthy life years, is to extrapolate
the available data on treatment benefit to a life-long
perspective using national vital statistics, which are regularly
employed to measure life expectancy. The objectives of this
investigation were to predict the impact of long-term
antihypertensive therapy in the prevention of cardiovascular
events. To this end we built a simple mathematical model,
which takes into account the treatment effect beyond the
usual duration of RCTs (life-long treatment for hyper-
tension) and the life expectancy measured from national
vital statistics. In addition, we explored the appropriateness
of the absolute and relative gain in event-free life expectancy
as comprehensive efficacy indices for quantifying the effect
of long-term preventive treatment for each age from 40 to
90 years.
Methods
To estimate the rate of cardiovascular (CV) and non CV
deaths in a hypothetical US population of untreated
hypertensive patients, we used the following procedure: age-
specific death rates in the US general population were
obtained from national vital statistics (1994), and in
untreated hypertensive population they were obtained from
the control groups of the Individual Data ANalysis of
Antihypertensive drug intervention trials (INDANA)
database (Gueyffier et al 1995). This latter group represents
a unique cohort of 14 942 untreated or placebo-treated
hypertensive patients, aged 26–96 with an average follow-
up of 5 years (Table 1). The INDANA death rate relative to
the US death rate was calculated for each age category and
summarized over all age groups using the Mantel Haenszel
(1959) estimator (no heterogeneity was found between the
age groups). US vital statistics were then multiplied by the
Mantel Haenszel estimate to extrapolate the death rate in
the US untreated hypertensive patients. The same procedure
was used to estimate the ratio of the rate of nonfatal events,
ie, stroke (ST), coronary heart disease (CHD), and major
cardiovascular events (CVE = ST + CHD), from the rate of
fatal events in the US general population. An illustrative
example is presented in Table 2.
The risk of death or cardiovascular events over time in
the US hypertensive population was then estimated using
the life-table method. Disease-free survival curves (ST,
CHD, and CVE) were built from 40 years until all patients
died (arbitrarily fixed at 101 years).
The treatment effect (hazard ratio) estimated from the
control and treated group of INDANA was applied to this
disease-free survival curve to obtain the disease-free survival
Table 1 Baseline characteristics of population included in INDANA database
Follow-up Treatment Number of patients Male Age
Study (years) allocated Treated Control (%) (mean)
MRC1 4.9 Placebo 8700 8654 52 52
EWPHE 4.7 Untreated 416 424 30 72
COOPE 4.4 Untreated 419 465 31 69
SHEP 4.5 Untreated 2365 2371 43 72
STOP 2.1 Untreated 812 815 37 76
MRC2 5.8 Placebo 2183 2213 42 70
Abbreviations: INDANA, Individual Data ANalysis of Antihypertensive drug intervention trials.
Table 2 Illustrative example of calculation method
INDANA Estimated Estimated
hypertensive population US stroke non fatal stroke rate non fatal stroke rate
Age stroke non fatal ratea  fatal rate SMR    in US untreatedb   in US treatedc
26–50 0.00083 0.00007 11.03 0.00029 0.00018
51–60 0.00308 0.00037 8.35 0.00145 0.00090
61–70 0.00808 0.00099 8.14 0.00391 0.00242
71–93 0.01270 0.00576 2.21 0.02269 0.01407
a Rate for 100 000 patients per year.
b Non fatal stroke rate in US untreated population was obtained by multiplying US fatal stroke rate by Mantel Haenzsel estimator (= 3.94).
c Non fatal stroke rate in treated population was obtained by multiplying the rate in untreated population by the hazard ratio (= 0.62).
Abbreviations: INDANA, Individual Data ANalysis of Antihypertensive drug intervention trials; SMR, standardized mortality ratio.Vascular Health and Risk Management 2005:1(2) 165
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curve of the life-long treated population. The treatment effect
was considered constant over time.
The gain in life expectancy without ST, CHD, and CVE
was estimated from the area between the two survival curves
of treated and control groups (Naimark et al 1994). The
relative gain in life expectancy was defined as the ratio of
gain in life expectancy to life expectancy.
The secular trends in mortality rates in the US were
integrated into our model using a linear regression model
(R
2 = 0.89, p < 0.001) estimated from the US census (US
DHHS 1995) of 1975–1997. The final models and estimators
used in our simulation are presented in Appendix 1.
As the quality of reporting cause of death is dubious, a
sensitivity analysis was performed to measure the possible
impact of such classification errors in the estimation of GLE
by our method. The GLE was estimated assuming an
overestimation of 25% in cardiovascular death certification
(Lloyd-Jones et al 1998; Coady et al 2001). (Simulations
were carried out using Mathematica™ software.)
Results
Results of the simulation are presented in Table 3. They
show a modest GLE without CHD and a more substantial
GLE without ST or CVE in both sexes. When hypertension
is diagnosed and treated in a man at 40 years of age, the
GLE is 20 months without CHD, 32 without ST, and 33
without CVE. These gains decrease slowly with increasing
age at the beginning of the treatment. At 70 years, the GLE
is 10 months without CHD and 17 months without ST.
However, the relative gain in life expectancy (RGLE)
increases with age. The RGLE without stroke for men rises
from 7% at 40 to 13% at 70 years. Figures 1 and 2 illustrate
how the GLE decreases and the RGLE rises with increasing
duration of treatment in men.
Both GLE and RGLE are higher in men than in women.
Gains are generally modest in women for all outcomes
(Table 2). On the other hand, as shown in Figure 3, when
comparing the GLE without stroke between men and
women, the GLE in women reaches a peak at 70 years, then
decreases.
In Tables 3 and 4, we compare the usual efficacy indices,
ie, relative risk and absolute risk reduction computed after
10 years of treatment with the assumption of a constant
treatment effect over time, with the GLE and RGLE at
different ages in men. A 40-year-old man treated for
hypertension has a relative risk of stroke of 0.80, an absolute
Table 3 Absolute and relative gain in life expectancy without events
Age at treatment initiation
40 years 50 years 60 years 70 years
Women Men Women Men Women Men Women Men
CHD GLE (months) 9.0 20.3 10.0 16.6 10.6 13.3 10.3 10.3
RGLE (%) 2.0 4.5 2.7 5.18 3.7 6.2 5.2 8.1
Stroke GLE (months) 14.2 32.2 15.7 26.0 16.5 21.0 16.2 16.9
RGLE (%) 3.1 7.0 4.3 7.9 5.9 9.6 8.5 13.2
CVE GLE (months) 19.2 32.6 21.3 27.0 22.1 21.5 21.3 16.5
RGLE (%) 4.3 7.8 5.9 9.2 8.4 11.2 11.5 15.0
Abbreviations: CHD, coronary heart disease; CVE, cardiovascular events; GLE, gain in life expectancy without events; RGLE, relative gain in life expectancy without
events.
Figure 2 Gain in event-free life expectancy (GLE) in men (months).
Abbreviations: CVE, cardiovascular events; ST, stroke; CHD, coronary
heart disease.
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Figure 1 Relative gain in event-free life expectancy (RGLE) (%) in men.
Abbreviations: CVE, cardiovascular events; ST, stroke; CHD, coronary
heart disease.
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benefit of 0.4% after 10 years, a GLE of 32 months or a
RGLE of 6% without stroke for his whole life. The absolute
benefit increases up to 6% and the GLE decreases to 15
months when hypertension is diagnosed and treated at 70
years.
Sensitivity analysis
More than 99% of deaths occurring in the US are registered
(US DHHS 1994). Thus, to perform a sensitivity analysis
we took into account the possible misclassification of cause
of death that occurred in the 1990s ten-year census. We
assumed 25% overestimation in death from stroke, CHD,
and CVE (stroke and CHD) classifications. The mis-
classification of cardiovascular causes of death had no major
influence on the results (Table 5). The maximum variation
observed in measured GLE was 3 months.
Discussion
We extrapolated a hypothetical US untreated hypertensive
population from national vital statistics and individual
patient data of untreated or placebo treated participants in
RCTs. To estimate the GLE without cardiovascular events
achieved with antihypertensive therapy we applied the
treatment effect estimated from RCTs to these hypertensive
patients.
National vital statistics are widely available and are used
to measure the life expectancy of populations with life-table
methods. However, one limitation of this approach is that
cross-sectional data are used longitudinally (life-table
method); ie, as if the rate for a 40-year-old individual after
20 years follow-up was the same as the one of a 60-year-
old 20 years ahead. This computation assumes the absence
of any secular trend. To decrease the impact of this
drawback, we took into account the secular trends in all
death rates from 1975 to 1997 in the US population. When
available, cohort studies on secular trends can determine
precisely whether age has the same effects on CV risk for
those born in different decades (Lloyd-Jones et al 1999;
Lloyd-Jones et al 2004), and their results could then be
integrated into our model.
Extrapolating the risk of death or cardiovascular events
in the general population from the control group of
participants in RCTs, could also lead to unrealistic results,
because study populations included in RCTs are not entirely
representative of the population at risk. However, INDANA
is a unique database because it includes data about
hypertensive, untreated, or placebo-treated patients that are
followed-up for on average five years. This provides the
most reliable available measurement of the hazard of
cardiovascular events.
Previous analyses with similar aims are based on the
isotropy hypothesis. This hypothesis asserts that the
preventive effect of antihypertensive or hypocholesterolemic
treatments on clinical events is solely and entirely
explained by the risk factor reduction (Taylor et al 1987;
Tsevat et al 1991; Grover et al 1998; Ulrich et al 1999, 2000;
Montgomery et al 2003). For instance, Tsevat et al (1991)
have reported that reducing diastolic blood pressure to
88 mmHg if > 88 mmHg will lead to 13 months GLE in a
Table 4 Comparison between traditional efficacy indexes, Gle and RGle in men
Coronary heart disease Stroke
Age AB
b RGLE
e AB Gle
(years) RR
a (%) NNT
c GLE
d  (%) RR  (%) NNT  (months) RGle
40 0.86 0.3 333 20 4.1 0.80 0.4 250 32 5.9
50 0.88 1.0 100 17 4.3 0.84 1.0 100 26 5.7
60 0.90 1.9 53 13 3.4 0.86 2.3 44 21 7.1
70 0.91 3.9 26 10 5.4 0.87 5.7 18 17 9.1
a Relative risk at 10 years.
b Absolute benefit at 10 years.
c Number needed to treat to avoid one event.
d Gain in life expectancy in months without events.
e Relative gain in life expectancy without events.
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Figure 3 Gain in life expectancy (GLE) without stroke (months).Vascular Health and Risk Management 2005:1(2) 167
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35-year-old male. However, the isotropy hypothesis seems
not to hold true in hypertension (Gueyffier and Boissel
1999). Our approach, assessing a patient’s GLE by
multiplying the baseline risk of death or cardiovascular
events, by the treatment effect (hazard ratio) estimated from
a systematic overview, performed on a large individual
patient database, seems more realistic (Boissel et al 1998).
With our method the estimated CHD-free GLE in a 35-year-
old man is 22 months.
Further analyses must assess the impact of treatment-
time interaction over the length of follow-up as well as the
trend of hypertension self-aggravation (Psaty et al 1997).
Variation of the treatment effect seems to be significant for
stroke (Boutitie et al 1998) and vary between different
classes of antihypertensives (ALLHAT 2002). However,
because we were not able to quantify this variation, we
considered the treatment effect constant over time. In a
hypothetical hypertensive French population, an arbitrary
increase or decline of treatment effect could highly influence
the GLE (Kassai et al 2001).
To predict the benefit of starting treatment early, we must
also take into account the risk associated with the history of
hypertension. For instance, in the female subgroup, one
cannot conclude that the GLE does not vary significantly,
no matter what age treatment is begun.
The robustness of our results to sensitivity analysis for
misclassification of causes of death shows that the use of
largely available life-table data can be generalized to forecast
gain in life expectancy, taking into account competing risks
and population particularities.
Our results highlight two major consequences of long-
term preventive therapy: first, the gain in life expectancy
declines and the relative gain in life expectancy rises with
age. These results balance guidelines based solely on the
absolute risk in the decision-making process. Second, our
simulation demonstrates the difficulty in estimating the
benefit of long-term therapy in low-risk (young) patients,
by short-term RCTs.
We believe that the absolute and RGLE calculated by
our simple method is a relevant decision tool, when correctly
understood by the patient and their healthcare providers
(Naimark et al 1994). These tools should be available in
daily practice through tables or a simple pocket calculator.
The GLE seems more relevant to describe long-term benefit
from preventive therapy than relative risk or absolute benefit
(Wright and Weinstein 1998; Tan and Murphy 1999). At
least, they helpfully complete the use of absolute benefit
expected from various therapies, recommended in recent
guidelines. There are few data available on whether the
results of RCTs expressed in terms of probability of
successful treatment could facilitate shared decision making
(Barry et al 1995; Lenert and Cher 1999). Further work is
needed to determine whether patients and healthcare
providers correctly understand these efficacy indices.
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Appendix 1
Mathematical model used for estimating the hazard of death or event in US hypertensive population.
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